Analyst Price Targets — RNA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 6, 2026 10:09 am | — | H.C. Wainwright | $25.00 | $11.74 | TheFly | Atrium Therapeutics initiated with a Buy at H.C. Wainwright |
| June 18, 2026 10:54 am | — | Cantor Fitzgerald | $25.00 | $12.48 | TheFly | Atrium Therapeutics initiated with an Overweight at Cantor Fitzgerald |
| May 15, 2026 10:13 am | — | Leerink Partners | $25.00 | $13.27 | TheFly | Atrium Therapeutics initiated with an Outperform at Leerink |
Latest News for RNA
SAN DIEGO, Sept. 2, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today announced that it will participate in upcoming investor conferences in September.
SAN DIEGO, Aug. 20, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company") today announced it awarded inducement grants on August 20, 2026 under the Company's 2026 Employment Inducement Incentive Award Plan (the "2026 Inducement Plan") as a material inducement to the employment of one non-executive individual newly hired by the Company. The employee received, in the aggregate, non-qualified…
-- IND clearance for ATR 1072 and launch of Corventis Phase 1/2 trial in PRKAG2 syndrome -- -- Achieved second milestone payment under global cardiovascular collaboration with Bristol Myers Squibb -- SAN DIEGO, Aug. 13, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) ("Atrium," "Atrium Therapeutics," or the "Company"), a biopharmaceutical company advancing precision cardiology by developing RNA…
SAN DIEGO, Aug. 13, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) ("Atrium," "Atrium Therapeutics" or the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics to the heart, today announced it has earned another $15 million milestone payment from Bristol Myers Squibb (NYSE: BMY) based on the successful delivery of a lead compound targeting an undisclosed cardiology…
Wall Street analysts made some dramatic moves on Thursday, slashing price targets by double digits on several high-profile names while upgrading others to buy. Find out which stocks got the most surprising treatment before the opening bell.
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for RNA.
Senate Trading
No Senate trades found for RNA.
U.S. House Trading
No House trades found for RNA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.